Prism Medico & Pharmacy Intrinsic Value
PRISMMEDI Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹7.20 | ₹5.76 - ₹8.64 | -63.3% | EPS: ₹0.60, Sector P/E: 12x |
| Book Value Method | asset | ₹17.33 | ₹15.60 - ₹19.06 | -11.7% | Book Value/Share: ₹21.67, P/B: 0.8x |
| Revenue Multiple Method | revenue | ₹39.24 | ₹35.32 - ₹43.16 | +100.0% | Revenue/Share: ₹46.67, P/S: 1.0x |
| PEG Ratio Method | growth | ₹5.89 | ₹5.30 - ₹6.48 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹5.89 | ₹5.30 - ₹6.48 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹17.10 | ₹15.39 - ₹18.81 | -12.8% | EPS: ₹0.60, BVPS: ₹21.67 |
Want to compare with current market value? Check PRISMMEDI share price latest .
Valuation Comparison Chart
PRISMMEDI Intrinsic Value Analysis
What is the intrinsic value of PRISMMEDI?
Based on our comprehensive analysis using 6 different valuation methods, the estimated intrinsic value of Prism Medico & Pharmacy (PRISMMEDI) is ₹17.10 (median value). With the current market price of ₹19.62, this represents a -12.8% variance from our estimated fair value.
The valuation range spans from ₹5.89 to ₹39.24, indicating ₹5.89 - ₹39.24.
Is PRISMMEDI undervalued or overvalued?
Based on our multi-method analysis, Prism Medico & Pharmacy (PRISMMEDI) appears to be trading above median value by approximately 12.8%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Debt to Equity Ratio | 1.62 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.33x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Prism Medico & Pharmacy
Additional stock information and data for PRISMMEDI
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2019 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2018 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2017 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |